A 12-year follow-up of ANNA/C-TRUS image-targeted biopsies in patients suspicious for prostate cancer.

B M Zeeshan HameedBjörn GrabskiUdo PaulLeif BäurleTillmann Loch

Published in: World journal of urology (2017)

ANNA/C-TRUS is a useful method monitoring patients with a risk of PCa. 50-75% of the usually performed biopsy cores could be spared and, after 12 years, 97% of the patients were either without evidence of a PCa or were diagnosed with a good prognosis tumor.

Keyphrases

prostate cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
drug delivery
radical prostatectomy
cancer therapy
patient reported